Unichem Laboratories liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

4.17×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.48×	2.48×	2.05×	2.39×	2.48×
1.38×	1.38×	1.05×	1.40×	1.51×
289	289	89.6	152	185
1,311	1,311	1,038	986	949

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

UNICHEMLAB₹488.80

Unichem Laboratories Limited

· Pharma & Health

₹ CrorePeersGUFICBIO RPGLIFE GUJTHEM SMSPHARMA ORCHPHARMA INDSWFTLAB SOLARA FDCMcap ₹3,441 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	4.17
Current Ratio	2.48	2.39	2.05	2.48	2.48
Quick Ratio	1.51	1.40	1.05	1.38	1.38
Cash, Equiv & ST Investments	185.3	152.3	89.6	289.5	289.5
Working Capital	948.9	986.3	1,037.5	1,311.4	1,311.4

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.